D. Western Therapeutics Institute Inc
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract su… Read more
D. Western Therapeutics Institute Inc (6DW) - Total Liabilities
Latest total liabilities as of June 2025: €628.89 Million EUR
Based on the latest financial reports, D. Western Therapeutics Institute Inc (6DW) has total liabilities worth €628.89 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
D. Western Therapeutics Institute Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how D. Western Therapeutics Institute Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
D. Western Therapeutics Institute Inc Competitors by Total Liabilities
The table below lists competitors of D. Western Therapeutics Institute Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oba Makarnacılık San As
IS:OBAMS
|
Turkey | TL2.35 Billion |
|
Opticis Company Limited
KQ:109080
|
Korea | ₩5.86 Billion |
|
Wooyang Co. Ltd
KQ:103840
|
Korea | ₩105.14 Billion |
|
Rubenis Tekstil Ticaret A.S.
IS:RUBNS
|
Turkey | TL836.44 Million |
|
Northstar Clean Technologies Inc
OTCQB:ROOOF
|
USA | $53.06 Million |
|
Keck Seng Investments (Hong Kong) Limited
PINK:KCKSF
|
USA | $1.90 Billion |
|
Generation Bio Co
NASDAQ:GBIO
|
USA | $71.34 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down D. Western Therapeutics Institute Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how D. Western Therapeutics Institute Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for D. Western Therapeutics Institute Inc (2009–2024)
The table below shows the annual total liabilities of D. Western Therapeutics Institute Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €935.58 Million | -14.45% |
| 2023-12-31 | €1.09 Billion | +0.99% |
| 2022-12-31 | €1.08 Billion | +153.18% |
| 2021-12-31 | €427.72 Million | -25.46% |
| 2020-12-31 | €573.81 Million | +0.09% |
| 2019-12-31 | €573.27 Million | -25.90% |
| 2018-12-31 | €773.65 Million | -1.02% |
| 2017-12-31 | €781.62 Million | +2099.58% |
| 2016-12-31 | €35.53 Million | +22.53% |
| 2015-12-31 | €29.00 Million | +22.31% |
| 2010-12-31 | €23.71 Million | -11.20% |
| 2009-12-31 | €26.70 Million | -- |